Kent Hutchison
kent.hutchison@cuanschutz.edu · University of Colorado, Denver · Director, Neurogenetics Core, The Mind Research Network
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kent Hutchison as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05632627 · Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled TrialUniversity of Colorado, Denver · completed · Brain Injuries, Traumatic · principal investigator
- Ph2/Ph3NCT05613608 · Alcohol Use Disorder and CannabidiolUniversity of Colorado, Denver · recruiting · Alcohol Use Disorder · principal investigator
- N/ANCT03522103 · Cannabis Observational Study on Mood, Inflammation, and CognitionUniversity of Colorado, Denver · completed · Inflammation, Inflammatory Response, Mood · principal investigator
- Ph4NCT01228175 · Effectiveness of Varenicline: Testing Individual DifferencesThe Mind Research Network · completed · Smoking Addiction · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Administrative CoreP50DA056408 · NIDA · UNIVERSITY OF COLORADO DENVER · fiscal years 2023 to 2026 · $283,040 awarded in 2026Same name and institution; not confirmed by an ID
- Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction StrategiesR01AA029606 · NIAAA · UNIVERSITY OF COLORADO DENVER · fiscal years 2022 to 2026 · $501,086 awarded in 2026Grant number is on one of their registry trials
- Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled TrialR01AG079502 · NIA · UNIVERSITY OF COLORADO DENVER · fiscal years 2023 to 2026 · $712,810 awarded in 2026Same name and institution; not confirmed by an ID
- Psilocybin Outside the Clinic: A Comprehensive Study of Acute and Long-Term Effects on Mood and BehaviorR01DA064555 · NIDA · UNIVERSITY OF COLORADO DENVER · fiscal years 2026 · $628,657 awarded in 2026Same name and institution; not confirmed by an ID
- CORE FUNCTION ACTIVITIES TASK ORDER FOR ADVISORY SERVICES AND ADMINISTRATIVE REPORTING. TASK ORDER NUMBER 75N94021D00016 75N94021F00001 ADMINISTRATIVELY REPLACES TASK ORDER NUMBER 75N94021D00009 75N975N94021D00 · NICHD · UNIVERSITY OF COLORADO DENVER · fiscal years 2021 to 2024 · $36,253 awarded in 2024Same name and institution; not confirmed by an ID
- Hemp-derived Cannabidiol for the treatment of cannabis use disorder in concentrate users: A double-blind placebo-controlled randomized trialR01DA059234 · NIDA · UNIVERSITY OF COLORADO · fiscal years 2023 to 2024 · $98,952 awarded in 2024Same name and institution; not confirmed by an ID
- Novel Approaches to Opiate Use ReductionR01DA048069 · NIDA · UNIVERSITY OF COLORADO DENVER · fiscal years 2020 to 2024 · $591,853 awarded in 2024Same name and institution; not confirmed by an ID
- Cannabis for Palliative Care in Cancer: A Placebo-controlled Randomized Trial of Full Spectrum Hemp-derived CBD/THCR01CA284860 · NCI · UNIVERSITY OF COLORADO · fiscal years 2023 · $650,978 awarded in 2023Same name and institution; not confirmed by an ID
- Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of ActionR01AA024632 · NIAAA · UNIVERSITY OF COLORADO DENVER · fiscal years 2016 to 2020 · $565,804 awarded in 2020Same name and institution; not confirmed by an ID
- Marijuana Harm Reduction: Innovative Strategies for Developing New KnowledgeR01DA039707 · NIDA · UNIVERSITY OF COLORADO · fiscal years 2016 to 2020 · $200,780 awarded in 2020Same name and institution; not confirmed by an ID
- Alcohol Dependence: Integrating Genetic & fMRI MethodsR01AA012238 · NIAAA · THE MIND RESEARCH NETWORK · fiscal years 2000 to 2014 · $495,636 awarded in 2014Same name and institution; not confirmed by an ID
- Effectiveness of Varenicline: Testing Individual DifferencesR01DA025074 · NIDA · THE MIND RESEARCH NETWORK · fiscal years 2009 to 2014 · $698,488 awarded in 2014Grant number is on one of their registry trials
- Sensitivity to Intravenous Ethanol: Genetic DeterminantsR01AA015968 · NIAAA · THE MIND RESEARCH NETWORK · fiscal years 2007 to 2011 · $328,062 awarded in 2011Same name and institution; not confirmed by an ID
- A New Pharmacotherapy for Alcohol Dependence: OlanzapineR01AA014886 · NIAAA · THE MIND RESEARCH NETWORK · fiscal years 2006 to 2010 · $547,578 awarded in 2010Same name and institution; not confirmed by an ID
- A NEW PHARMACOTHERAPY FOR ALCOHOL DEPENDENCEM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · fiscal years 2004 to 2008 · $2,096 awarded in 2008Same name and institution; not confirmed by an ID
- Progression of Craving and Addiction: Genetic FactorsR01DA014642 · NIDA · UNIVERSITY OF COLORADO · fiscal years 2001 to 2005 · $294,000 awarded in 2005Same name and institution; not confirmed by an ID
- PSYCHOPHYSIOLOGICAL AND BEHAVIORAL MECHANISMS OF SMOKINGR21CA081637 · NCI · UNIVERSITY OF COLORADO · fiscal years 1999 to 2000 · $162,296 awarded in 2000Same name and institution; not confirmed by an ID
- STARTLE REFLEX--TESTING ALCOHOL PATIENTS AND TREATMENTSR29AA012238 · NIAAA · UNIVERSITY OF COLORADO · fiscal years 1998 to 1999 · $92,516 awarded in 1999Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:24 UTC. The ranking covers the 200 most relevant of 50 PubMed records, and a shared surname and initials can bring in a namesake. All 50 on PubMed
- Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.Arch Gen Psychiatry · 2007212 citationsRCR 6.5
- Exposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry.Neuropsychopharmacology · 2008181 citationsRCR 5.5
- Identifying neurobiological phenotypes associated with alcohol use disorder severity.Neuropsychopharmacology · 2011170 citationsRCR 5.7
- Naltrexone's effect on cue-elicited craving among alcoholics in treatment.Alcohol Clin Exp Res · 1999163 citationsRCR 5.7
- The DRD4 VNTR polymorphism moderates craving after alcohol consumption.Health Psychol · 2002117 citationsRCR 3.3
- A transdisciplinary model integrating genetic, physiological, and psychological correlates of voluntary exercise.Health Psychol · 2007105 citationsRCR 3.4
- Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction.Neuropsychopharmacology · 200397 citationsRCR 2.8
- Neural and behavioral mechanisms of impulsive choice in alcohol use disorder.Alcohol Clin Exp Res · 201194 citationsRCR 3.3
- The effect of olanzapine on craving and alcohol consumption.Neuropsychopharmacology · 200693 citationsRCR 2.9